Abstract
Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Current Enzyme Inhibition
Title: Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Volume: 7 Issue: 2
Author(s): Kalyan K. Sethi, Padilam Suresh and Sumanta Mondal
Affiliation:
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Abstract: Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Export Options
About this article
Cite this article as:
K. Sethi Kalyan, Suresh Padilam and Mondal Sumanta, Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius, Current Enzyme Inhibition 2011; 7 (2) . https://dx.doi.org/10.2174/157340811796575272
DOI https://dx.doi.org/10.2174/157340811796575272 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Evaluation of the Anticonvulsant Activity of 5-alkylthio-4- phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one Derivatives
Letters in Drug Design & Discovery Preface
Current Drug Targets - CNS & Neurological Disorders Synthesis and Anticonvulsant Activity of Some Novel Semicarbazone Containing Benzoxazole: Pharmacophore Model Study
Current Bioactive Compounds Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology The Progress of Epilepsy after Stroke
Current Neuropharmacology Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model
Current Neurovascular Research Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews